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Abstract
Interleukin-7 (IL-7) concentrations are increased in the blood of CD4+ T cell depleted individuals, including HIV-1 infected
patients. High IL-7 levels might stimulate T cell activation and, as we have shown earlier, IL-7 can prime resting T cell to
CD95 induced apoptosis as well. HIV-1 infection leads to B cell abnormalities including increased apoptosis via the CD95
(Fas) death receptor pathway and loss of memory B cells. Peripheral B cells are not sensitive for IL-7, due to the lack of IL-7Ra
expression on their surface; however, here we demonstrate that high IL-7 concentration can prime resting B cells to CD95-
mediated apoptosis via an indirect mechanism. T cells cultured with IL-7 induced high CD95 expression on resting B cells
together with an increased sensitivity to CD95 mediated apoptosis. As the mediator molecule responsible for B cell priming
to CD95 mediated apoptosis we identified the cytokine IFN-c that T cells secreted in high amounts in response to IL-7.
These results suggest that the lymphopenia induced cytokine IL-7 can contribute to the increased B cell apoptosis observed
in HIV-1 infected individuals.
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Introduction
Interleukin-7 acts as a survival factor for resting peripheral T
cells via the maintenance of cellular homeostasis and by promoting
the expression of anti-apoptotic proteins. In addition, IL-7 can
serve as a costimulatory factor during T cell activation, a role that
is particularly important in conditions associated with lymphope-
nia when IL-7 triggers hoemostatic proliferation. The progressive
loss of peripheral T lymphocytes in HIV-1 infected individuals, as
well as in other lymphopenic conditions, has been associated with
increased concentrations of IL-7, and higher IL-7 levels could
possibly contribute to the accelerated T cell activation [1,2,3].
Although the potential effects of the lymphopenia induced higher
IL-7 levels remain speculative, animal models indicated that the
modulation of IL-7 levels has a strong impact on T cell homeostasis.
Increased T cell numbers and signs of autoimmunity were detected
at higher IL-7 doses, whereas a higher competition for IL-7 via IL-
7Ra overexpression led to decreased T cell numbers [4,5,6,7,8].
In our previous studies we showed that the IL-7 induced T cell
stimulation can lead to increased sensitivity to activation induced
apoptosis via the CD95 death receptors [9,10]. IL-7 increased
the expression of the CD95 on resting T cells, induced a polarized
cell surface distribution of the molecule and increased the
sensitivity of T cells to CD95 mediated apoptosis. Serum IL-7
levels correlated with CD95 expression and apoptosis sensitivity of
T cells in HIV-1 infected patients further indicating a potential
link between high IL-7 levels and increased T cell apoptosis in
lymphopenic conditions [9].
Normally, CD95 molecules play an important role in regulating
T and B cell homeostasis. Activated T and B lymphocytes both
up-regulate CD95 expression and require anti-apoptotic signals to
escape CD95 mediated apoptosis. Among B cells, the ones
receiving strong BCR signals via high affinity antigen recognitions
are able to avoid CD95-induced apoptosis. On the other hand,
weakly activated B cells or others receiving bystander T cell-
derived signals only are likely to undergo apoptosis [11]. Based on
this model, activation-induced sensitivity to CD95 mediated
apoptosis might help the selection of B cells that carry high
affinity antigen receptors during the course of B cell activation.
B cells are not the main targets of HIV-1 infection, but their
defects have been described very early after the discovery of HIV-
1 [12]. B cell subsets associated with immature, exhausted or
activated apoptosis-prone phenotype accumulate in the circulation
probably underlying decreased B cell functionality, increased B
cell turnover and the loss of serological memory against pathogens
[13,14,15]. The CD95 moelcules have been extensively implicated
in both T and B cell apoptosis occurring in HIV-1 infected
individuals. CD95 expression is elevated on T and B lymphocytes
during HIV-1 infection, possibly as a consequence of the chronic
and generalized immune-cell activation [13,16,17,18,19,20,21,22].
The increased CD95 expression of B cells has been primarily
associated with active viral replication during HIV-1 infection
[13], however, ART does not lead to normalization of CD95
expression and B cell survival during chronic HIV-1 infection,
indicating the presence of viremia-independent mechanisms that
prime B cells to CD95-mediated apoptosis [22].
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28629The lymphopenia induced cytokine IL-7 may not act directly on
peripheral B cells due to the lack of IL-7Ra expression on these
cells. On the other hand, high IL-7 levels have been associated
with the accumulation of immature, transitional B cells in the
circulation of lymphopenic patients indicating a potential impact
of altered IL-7 levels on B cell homeostasis [23,24].
In the present study we identified a novel regulatory mechanism
that can lead to increased CD95 mediated B cell apoptosis in the
presence of high IL-7 concentrations. IL-7 induced high CD95
expression on resting B cells and increased the sensitivity to CD95
mediated apoptosis via the cytokine IFN-c that was produced by
IL-7 treated T cells. These results indicate a potential link between
high IL-7 levels and the increased B cell turnover during HIV-1
infection. In addition, our findings may also help to understand the
events leading to decreased B cell numbers in patients receiving
IL-7 therapy [25].
Materials and Methods
Cell culture
Blood samples were obtained from healthy blood donors (buffy
coats). The ethical committeeatthe Karolinska Institutet approved our
studies involving human samples. Peripheral blood mononuclear cells
(PBMCs) were separated by Ficoll gradient centrifugation (Lympho-
p r e p ,N o r w a y ) .F o rc e l lc u l t u r e s ,m o n o c y t e s ,Ta n dBl y m p h o c y t e s
were separated using respectively the CD14 human microbeads, the
Pan T cell Isolation Kit and B cells isolation kit II (Miltenyi Biotech,
Bergisch Gladbach, Germany). The purity of the selected cell
populations was 90–97% as measured by flow cytometry. Cells were
cultured at a density of 1610
6 cells/ml in RPMI-1640 containing L-
glutamine, 10% FCS and antibiotics. Human recombinant IL-2, IL-4,
IL-7, IL-15 and IL-21 were all purchased from Peprotech (London,
UK). The STAT1 inhibitor Fluodarabine was purchased from Sigma,
S t .L o u i s ,M O .T h en e u t r a l i z i n gI F N - c antibody was purchased from
R&D Systems (Minneapolis, MN). For the generation of IL-7 treated
T cell supernatants, T cells were cultured in 25 ng/ml IL-7 and new
medium was added in every 2–3 days.
Flow cytometric analysis
The following fluorochrome-conjugated antibodies were used:
V450 BD Horizon anti-CD3 and anti-CD27, V500 anti-CD8,
FITC anti-CD19, PE anti-CD127 (IL-7Ra a) and anti-CD95, PE-
Cy5 anti-CD21, PE-Cy7 anti CD10 and anti CCR7, APC anti-
IFN-c and anti-CD95 (all from BD Pharmingen). PE-Texas Red-
conjugated anti-CD4 was purchased from AbCam, PerCP-Cy5.5
anti CD19 and anti CD45RA were purchased from BioLegend
and eBioscience respectively. Viable cells were detected using
Near-IR-Live/Dead kit (Invitrogen). For the detection of STAT1
phosporylation, CD19+ B cells were sorted from PBMCs using a
MoFlo XDP Cell Sorted (Beckman Coulter, CA) and cultured
with IL-7 treated T cells supernatant or control supernatant.
Phosphorylation of STAT1 was detected using an Alexa Fluor 647
anti-STAT1 (pY701) (BD Pharmingen). For the intracellular
staining of IFN-c T cells were separated from PBMCs and
cultured for 5 days in the presence or absence of IL-7 and further
activated with 50 ng/ml of phorbol myristate acetate (PMA) and
1 mM ionomycin (Sigma) for 6 hours in the presence of GolgiPlug
(BD Pharmingen). Fluorescence intensities were measured with
FACS LSR II (Becton Dickinson, CA) and data analysed with
FlowJo v. 8.4.4 software (Tree Star Inc.).
Apoptosis detection
CD95 mediated apoptosis was triggered by human recombinat
CD95L (1 mg/ml), cross-linked with 20 mg/ml anti-His antibody
(both from R&D System). FITC-conjugated Annexin V reagent
(BD Pharmingen) was used to measure apoptosis according to
manufacturer’s instructions. The fraction of cells Vivid negative-
Annexin V positive CD3 positive (T lymphocytes), or CD19
positive (B lymphocytes) were considered apoptotic.
Protein Array
Sorted B cells were incubated in IL-7 treated or non treated T
cell supernatants for 30 minutes and the phosphorylation patterns
was determined using the Human Phospho-Kinase Array Kit
(R&D Systems) according to manufacturer’s instruction.
Detection of IFN-c mRNA levels in T cells
Cellular RNA was isolated from T cells using TriZol
(Invritogen). Reverse transcription was performed with the High
Capacity cDNA Archive kit (Applied Biosystems). For the real-
time PCR we used human IFN-c and the Transferrin Receptor or
the Cyclophilin assays as endogenous controls, all from Applied
Biosystems. The cycling reactions were performed with a 7900
CD95T ABI PRISM Sequence Detector System (Applied
Biosystem).
Measurement of cytokine concentrations
IFN-c production was analysed in culture supernatants using
ELISA (BD Pharmingen) according to manufacturer’s recommen-
dations.
Results
IL-7 treated T cells induce CD95 upregulation on B cells
through the release of a soluble factor
We have previously shown that treatment of T cells in vitro with IL-
7upregulatesCD95expressionand primesTcellstoCD95mediated
apoptosis [9]. Interestingly, we observed that in IL-7 treated cultures
of peripheral blood mononuclear cells (PBMC) B cells upregulated
CD95 expression at a level comparable to T cells (Figure 1A). The IL-
7 induced CD95 upregulation wassimilarly observed onseveralB cell
subpopulations distinguished by the expression of CD10, CD21 and
CD27 [15], namely CD21
+CD27
2 naı ¨ve, CD21
+CD27
+ memory,
CD21
lowCD27
2 tissue-like memory, CD21
lowCD27
+ activated me-
mory,CD10
+CD27
2immature transitional,CD10
+CD27
+germinal
center-like B cells, as measured in PBMC cultured in presence of
25 ng/ml and 2.5 ng/ml IL-7 for five days (Figure 1B,C). The
comparable upregulation of CD95 on different B cell subsets in
presence of both high and low IL-7 concentrations indicates that
these distinct B cell populations have similar sensitivity to IL-7 effects.
Importantly, mature B cells do not express the IL-7Ra subunit
of the IL-7 receptor suggesting that IL-7 exerts its effect on B cells
through an indirect mechanism. In order to better understand the
mechanism leading to high CD95 expression on B cells in the
presence of IL-7 we studied whether CD95 was induced by IL-7
directly or alternatively, by IL-7 treated T cells via the release of a
B cell modulatory factor. B cells, isolated from peripheral blood of
healthy donors did not upregulate CD95 in the presence of IL-7
during a 3-day culture (Figure 1D). On the other hand, in the
presence of purified T cells, IL-7 efficiently induced CD95
expression on the majority of B cells. IL-7 treated T cells induced
comparable CD95 expression on B cells in co-culture experiments
or when the two cell types were separated in a trans-well system or
when supernatant of an IL-7 treated T cell culture was added to B
lymphocytes. These results indicated that IL-7 induced CD95
upregulation on B cells via a soluble mediator released by T cells.
To further demonstrate the indirect nature of the IL-7 effect on
CD95 expression of B cells, we treated purified B cells with the
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10 mg/ml neutralizing anti-IL-7 or isotype control antibodies.
These experiments showed that IL-7 neutralization did not
interfere with the ability of the IL-7 treated T cell supernatant
to induce CD95 upregulation on B cells (data not shown).
CD95 expression induced by IL-7 treatment of T cells
increases the sensitivity of B cells to CD95 mediated
apoptosis
CD95 mediated apoptosis is regulated not only by CD95L
availability but also by the expression level and membrane
organization of the receptor and by the interaction of several pro-
and anti-apoptotic factors influencing apoptotic signaling path-
ways [26]. Therefore, CD95 expression does not always correlate
with sensitivity to CD95 mediated apoptosis. We studied whether
the IL-7 induced high CD95 expression had an effect on B cell
survival upon experimental CD95 triggering. We cultured PBMCs
in the presence or absence of IL-7 for five days and monitored
CD95 expression and sensitivity to CD95L induced apoptosis of
both T and B lymphocytes at different time points. IL-7 induced a
slow upregulation of CD95 expression on T lymphocytes
accompanied by an increasing sensitivity of the cells to apoptosis
triggered by CD95L (Figure 2A). B cells in the same cultures
showed a similar, gradually increasing CD95 expression in
response to IL-7 that resulted in an elevated sensitivity to CD95
mediated apoptosis at day 5 of the culture. IL-7, added to the
PBMCs cultures, increased CD95 expression and CD95 mediated
apoptosis with a similar kinetics as supernatants of T cells
previously treated with IL-7 for five days. These results possibly
indicate that the slow upregulation of CD95 on B cells is not the
result of a delayed IL-7 effect on the CD95 inducing mediator
molecule but rather a slow effect of the mediator itself. Our results
Figure 1. Induction of CD95 upregulation on B cells by IL-7 treated T cells. A. Representative histogram of CD95 expression among T and B
lymphocytes from untreated (dashed line) or IL-7 treated (solid line) PBMCs cultured for 5 days. Grey filled histograms correspond to isotype control
stainings. B. Peripheral B cell subsets were distinguished by measuring CD10, CD21 and CD27 expression. A representative CD95 staining on B cell
subsets is shown after culturing PBMC for 5 days in presence (solid line) or absence (dashed line) of IL-7. Data are representative of 3 independent
experiments. C. Cell surface levels of CD95 on different B cell subsets are shown measured after culturing PBMCs for 5 days in the presence of 25 or
2.5 ng/ml IL-7, or without the cytokine. D. Analysis of CD95 expression on freshly purified B cells or following a 3 day culture with and without IL-7.
Alternatively, purified B cells were co-cultured with T cells using 1:1 cell ratio allowing direct cell contact or separating the cells using a trans-well
system. B cells were also plated in the presence of IL-7 treated or non treated T cell supernatants collected after culturing T cell for 5 days in the
presence or absence of 25 ng/ml IL-7. Data are representative of 5 experiments.
doi:10.1371/journal.pone.0028629.g001
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upregulation of CD95 on B cells leads to a higher sensitivity to
CD95 mediated apoptosis, suggesting a potential link between
lymphopenia and B cell apoptosis.
T cells treated with IL-7 induce STAT1 activation in B cells
Expression of CD95 on lymphocytes is primarily a consequence
of antigenic stimulation, and B cells can also express CD95 as
result of CD40 engagement during a germinal center reaction
[11]. Other signaling pathways leading to upregulation of CD95
on B cells are still elusive. In our setting, CD95 upregulation on B
cells by IL-7 treated T cells was not affected by an antibody
blocking CD40-CD40L interaction and T cells cultured for 5 days
in the presence of IL-7 remained negative for CD40L suggesting
that IL-7-induced CD95 expression is independent of CD40
activation (data not shown). In order to identify the IL-7 induced
modulatory factor acting on B cells first we performed a molecular
weight-based filtering of the IL-7 treated T cell supernatants and
found that the factor inducing CD95 expression on B cells was
present in the MW range between 30–100 KD, thus excluding T
cell-derived exosomes or membrane fragments as mediators for
such activity (data not shown). Next we analyzed signaling
pathways induced in B cells by supernatants of IL-7 treated T
cells using a protein array detecting 46 individual phophorylation
events on different signaling components. Sorted B cells were
incubated in IL-7 treated or non-treated T cell supernatants for
30 minutes and thereafter the phosphorylation patterns induced in
B cells were compared. We consistently observed an increased
STAT1 phophorylation on residue Y701 in response to the IL-7
treated T cells supernatant (Figure 3A). In order to validate this
protein array data we incubated sorted B cells with supernatant of
IL-7 treated or non treated T cell cells and analyzed Y701
phophorylation of STAT1 using flow cytometry. As shown in
figure 3B, IL-7 treated T cell supernatant induced a marked
STAT1 phosphorylation in B cells whereas non treated T cell
supernatants had no effect on STAT1 (Figure 3B). In order to
evaluate the relevance of STAT1 activation in the increase of
CD95 expression on B cells we cultured sorted B cells with IL-7
treated or non-treated T cell supernatant in the presence of
Fluodarabine, a known STAT1 inhibitor [27]. As shown in
Figure 3C, Fluodarabine decreased considerably the upregulation
of CD95 on B cells in presence of IL-7 treated T cell supernatants,
strongly suggesting that STAT1 serves as a signaling mediator of
the IL-7 induced effects on B cells.
IFN-c acts as an IL-7 induced mediator that upregulates
CD95 expression on B cells
STAT1 is posphorylated in response to both type I and II
interferons; however, whereas type I IFNs induce signaling
through STAT1/STAT-2 heterodimers, IFN-c mediates its effects
by inducing STAT1 homodimers [28,29]. We did not detect
phoporylation of STAT-2 or other STATs by protein array
Figure 2. Enhanced CD95 mediated apoptosis of T and B cells upon IL-7 treatment. Kinetics of CD95 expression (left panels) and CD95
mediated apoptosis sensitivity (right panels) of CD3+ T cells (A) and CD19+ B cells (B) are shown, measured in PBMC cultures treated with 25 ng/ml
IL-7, with supernatants of IL-7 treated or non treated T cell cultures or left untreated. Apoptosis was triggered using recombinant CD95L added for
24 hours to cultures. Data are representative of 3 independent experiments.
doi:10.1371/journal.pone.0028629.g002
Role of IL-7 in CD95 Mediated B Cell Apoptosis
PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e28629(Figure 3A) suggesting IFN-c as a possible mediator of IL-7 effects
on B cells. In addition, it has been shown that IFN-c can induce
CD95 expression on transformed cell lines of various origin and
IL-7 treatment increased IFN-c production by T cells triggered
with anti-CD3 and anti-CD28 antibodies [30,31,32]. In order to
test whether IL-7 induces IFN-c production by resting T cells we
measured IFN-c concentrations in supernatants of IL-7 treated or
non-treated T cell cultures.
Interestingly, IL-7 treatment induced the secretion of high levels
of IFN-c by T cells and the production remained stable during the
11 days of the experiment (Figure 4A). In non-treated T cell
cultures we detected a measurable IFN-c production in one donor
out of the seven tested in this experiment. Notably, in our
experiments IL-7 induced IFN-c secretion in a resting T cell
population, without concomitant TCR triggering. We detected
similar amounts of IFN-c produced by sorted CD4+ or CD8+ T
cells in response to IL-7 treatment in three different experiments
(data not shown). In order to identify the cellular source of IFN-c
in the IL-7 treated T cell cultures we studied IFN-c production in
CD4+ and CD8+ cells at various differentiation stages using
intracellular flow cytometry. In non IL-7 treated T cell cultures we
detected a small fraction of cells able to produce IFN-c that were
mostly memory cells (Figure 4B). Among CD8+ T cells the
CD45RA-CCR72 and the CD45RA+CCR72 effector memory
populations were enriched in IFN-c producing cells whereas naı ¨ve,
most CD4+ memory and CD8+ central memory T cells lacked the
ability to produce IFN-c. In cultures treated for 5 days with
25 ng/ml IL-7, the previously IFN-c negative T cells obtained the
ability to produce IFN-c at a low but clearly detectable level,
whereas T cells that already had the ability to secrete IFN-c
increased the production of the cytokine (Figure 4B). In addition,
among memory subsets, we detected a shift from low IFN-c
producer to high IFN-c producer profile, clearly detectable in
CD4+ effector memory and CD8+ central memory T cells. IL-7
may thus not only provide an additive effect on IFN-c production
by raising weakly and evenly the ability of all T cells to secrete this
cytokine, but it can induce high levels of IFN-c released from cells
previously lacking the ability of IFN-c production. In line with the
secretion of IFN-c by IL-7 treated T cells we detected increased
IFN-c mRNA levels in IL-7 treated T cells suggesting that IL-7
increases IFN-c transcription (Figure 4C).
Interestingly, the ability of supernatants collected from IL-7
treated and non-treated T cell cultures at the different time points
(Figure 4A) to induce CD95 expression of B cells correlated with
Figure 3. T cells treated with IL-7 induce STAT1 activation in B cells. A. B cells were purified from peripheral blood and were treated with
supernatants of T cells cultured with or without IL-7 for 30 minutes at 37uC. In order to identify signaling pathways specifically induced by the IL-7
treated T cell supernatants we lysed the B cells and used a protein array to detect a wide range of intracellular phophorylation events (see table).
Individual molecules are plotted in duplicates. B. STAT1 phosphorylation was studied in sorted B cells treated with supernatants of IL-7 treated or
non treated T cells using flow cytometry. C. CD95 expression on B cells cultured in the presence of the STAT1 inhibitor fluodarabine or DMSO control
in the presence of supernatants of IL-7 treated or untreated T cells. Data are representative of 3 independent experiments.
doi:10.1371/journal.pone.0028629.g003
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(p,0.0001, Figure 4D). These results strongly suggested that
IFN-c, secreted by T cells, might act as a mediator of IL-7 activity
on B cells. Indeed, culturing purified B cells with recombinant
IFN-c led to similar CD95 upregulation as observed in the
presence of the IL-7 treated T cell supernatants (Figure 4E). In
order to test whether the CD95 modulatory component in the
supernatants of IL-7 treated T cells is IFN-c, we cultured B cells
with IL-7 treated T cell supernatants in presence or absence of
IFN-c neutralizing antibodies. IFN-c neutralization efficiently
blocked the ability of IL-7 treated T cell supernatants to induce
STAT1 activation and CD95 upregulation in B cells (Figure 4F
and G respectively). Taken together, these findings show that IFN-
c, induced by IL-7 treatment of T cells, would in turn act on B
cells upregulating CD95 expression and increasing their sensitivity
to CD95 mediated apoptosis.
T cell mediated effect of the common c-chain cytokines
on CD95 expression of B cells
IL-7 signaling is transmitted by a receptor composed by the IL-
7Ra together with the common c-chain, a subunit shared by
several cytokines, including IL-2, IL-4, IL-7, IL-15 and IL-21.
Since IL-2 and IL-15 share the ability of IL-7 to induce CD95
expression on resting T cells [9], we tested whether the different c-
chain using cytokines could induce IFN-c production by T cells. T
cells were cultured for five days in the presence of the above
mentioned c-chain using cytokines and the culture supernatant
was tested for IFN-c concentration. Out of the five cytokines
tested, supernatants of IL-2, IL-7 and IL-15 treated T cells
contained high amount of IFN-c (Figure 5A) and induced CD95
upregulation on B cells (Figure 5B), whereas IL-4 and IL-21
showed no such activity. In order to demonstrate that the IL-2 or
IL-15 induced IFN-c production could lead to CD95 upregulation
on B cells we used neutralizing anti-IFN-c antibodies and showed
that IFN-c neutralization strongly reduce CD95 upregulation on B
cells induced by the IL-2 or IL-15 treated T cell supernatants
(Figure 5C).
Potential role of tissue environment on IL-7 induced IFN-
c production
It is predicted that T lymphocytes compete continuously for IL-
7 and T cell numbers are sensitively regulated by the availability of
the cytokine [33]. In addition to the concentration of IL-7, stromal
cells able to concentrate this cytokine on the cell surface and
deliver it to IL-7 sensitive cells may also have an impact on the
efficiency of IL-7 on target cells [34,35]. We tested whether the IL-
7 induced IFN-c production of T cells can be augmented by cell
types that present IL-7 on the cell surface. We detected that the
HS27 bone marrow derived cell line [36] bound high amounts of
IL-7 in an IL-7Ra independent manner (Figure 6A). Peripheral
blood monocytes also bound high amounts of IL-7; however these
cells expressed detectable level of IL-7Ra indicating that the
cytokine might simply be bound to its receptor. However, T cells
in the same samples were characterised by a clearly higher IL-7Ra
expression and by a similar or lower IL-7 binding ability as
compared to monocytes, thus indicating that monocytes accumu-
late at least part of the cell surface associated IL-7 independently of
the IL-7Ra molecules. The presence of the HS27 cell line had a
strong effect on the IL-7 induced IFN-c production in T cells
leading to detectable IFN-c production at otherwise insufficient
IL-7 concentrations and greatly increased IFN-c release at higher
IL-7 doses (Figure 6B). Monocytes, albeit less efficiently than the
bone marrow-derived stromal cells, could also increase IFN-c
production induced by IL-7. These results showed that the
stimulatory effect of IL-7 on IFN-c production is not only
determined by the concentration of free IL-7, but that stromal cells
surrounding T lymphocytes in the various tissues may also have a
strong impact on IL-7 efficiency.
Discussion
The cytokine IL-7 is often associated with increased T cell
activation in T cell depleted individuals due to its stimulatory
actions on survival and proliferation [37,38]. A close link between
CD4+ T cell depletion and increased blood IL-7 levels has been
demonstrated in HIV-1 infection and in other, non-HIV related
conditions of lymphopenia [1,2,23,39] possibly reflecting the
decreased IL-7 consumption associated with the loss of T cells.
The persistent increase of IL-7 levels might stimulate a chronic
and generalized T cell activation thus compensating the weakened
T cell responses [3,40]. On a long run, such non-antigen specific
stimuli can lead to autoimmune diseases as demonstrated in IL-7
transgenic mice [6,41].
Although it has been indicated that IL-7 production can be
inducible in the liver by TLR ligands [42], steady state IL-7
production by the non-immune stromal cells requires no ongoing
immune responses and the primary target cells for IL-7 are non-
activated naı ¨ve and memory T cells [33]. Thus the source and the
target cells clearly distinguish IL-7 from other c-chain using
cytokines that are typically produced during immune responses.
Chronically elevated IL-7 levels in lymphopenic conditions may
affect the majority of circulating peripheral lymphocytes in contrast
to IL-2, IL-4, IL-15 or IL-21 that are released at sites of ongoing
immune responses and act short term, on the population of
activated lymphocytes only. The abilities of IL-7 to support
peripheral T cell maintenance, contribute to homeostatic T cell
expansion in addition to stimulating the production of new T
lymphocytes made this cytokine an excellent candidate to improve
peripheral T cell numbers in lymphopenic individuals [43].
Figure 4. IL-7 induces CD95 upregulation on B cells via IFN-c released from T cells. A. Purified T cells were cultured in the presence or
absence of 25 ng/ml IL-7 and IFN-c concentrations were measured at the indicated time points using ELISA. Mean values and standard deviations are
calculated from the results of 7 independent experiments. B. IFN-c expression was analyzed by flow cytometry in naı ¨ve (CD45RA+CCR7+), central
memory (CD45RA-CCR7+), effector memory (CD45RA-CCR72) and TEMRA (CD45RA+CCR72) T cell subsets cultured in the presence (black line) or
absence (grey line) of 25 ng/ml IL-7 for five days. Dashed lines represent isotype control staining. Data are representative of 3 independent
experiments. C. IFN-c mRNA levels were measured in IL-7 treated or untreated T cells by real time PCR. D. IFN-c concentrations measured in the IL-7
treated or non-treated T cell supernatants are correlated with the ability of the same supernatants to induce CD95 expression on B cells (using the
samples described in panel A). Black dots represent IL-7 treated, white dots represent non treated T cell supernatants collected at day 2, 5, 8 or 11.
E. CD95 expression is shown on freshly isolated B cells (dashed line) or following a 12 h (grey lines) or 48 h (black lines) treatment with IL-7 treated T
cell supernatants or 20 ng/ml recombinant human IFN-c. F. STAT-1 phosphorylation is measured using flow cytometry in sorted B cells treated with
supernatants of IL-7 treated T cells in combination with 10 mg/ml neutralizing anti-IFN-c or isotype control antibodies. Data are representative of 3
experiments. G. B lymphocytes were cultured for five days with IL-7 treated or non treated T cell supernatants or were left untreated in the presence
of 10 mg/ml neutralizing anti-IFN-c or isotype control Abs. Thereafter the expression of CD95 was analyzed by flow cytometry. Data are
representative of 3 different experiments.
doi:10.1371/journal.pone.0028629.g004
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of IL-7Ra expression on these. On the other hand, an intriguing
correlation has been detected between IL-7 concentrations in
human serum and the ratio of immature transitional B
lymphocytes in HIV-1 infected individuals and in idiopathic
CD4+ T cell lymphopenia [23,24]. In addition, IL-7 therapy in
humans led to transiently increased ratios of circulating transi-
tional B cells [44,45,46]. Although the mechanism by which IL-7
leads to increased circulating levels of transitional B cells is yet to
be clarified, the correlation between IL-7 levels and transitional B
cell ratios indicates a potential influence of IL-7 on B cell
homeostasis.
HIV-1 infection is associated with an increased sensitivity to
activation-induced apoptosis among peripheral T cells, probably
as a result of chronic and generalized activation of the immune
system [21,47]. The death receptors or ligands implicated in
bystander apoptosis of non HIV-1 infected T cells are CD95 and
TNF, induced by chronic T cell activation, and TRAIL, induced
by plasmacytoid DC-derived IFN-alpha [48]. In our previous
studies we showed that elevated IL-7 levels may not only support
T cell activation during HIV-1 infection but can also contribute to
T cell depletion through CD95 mediated apoptosis. We showed
that CD95 expression, CD95 surface polarization and sensitivity
to CD95 mediated apoptosis were all increased by IL-7 in resting
peripheral T cells [9,10]. The priming effect of IL-7 for CD95
mediated apoptosis might be particularly important in HIV-1
infected patients due the accelerated activation of both the
adaptive and the innate immune system that could lead to
increased Fas-L availability [49,50].
Similarly to T cells, B cells also show an increased activation
and apoptosis sensitivity during HIV-1 infection [13]. The
increased sensitivity of B cells to apoptosis is accompanied by a
decreased memory B cell ratios and loss of serological memory to
pathogens [51,52]. In our study we identified a novel mechanism
through which IL-7 can increase CD95 expression and apoptosis
sensitivity of peripheral B cells via the induction of IFN-c in T
cells. IFN-c, released by IL-7 treated T cells, induced STAT1
phosporylation and CD95 upregulation in B cells. In addition, the
IL-7 induced CD95 expression was associated with higher
apoptosis sensitivity upon experimental CD95 ligation. These
results indicate that the increasing IL-7 levels in HIV-1 infected
individuals may contribute to CD95 mediated depletion of
peripheral B lymphocytes. In line with this hypothesis, IL-7
therapy in humans resulted in a significant decline in peripheral B
cell numbers that was reverted 1–2 weeks after cessation of the
therapy [25]. Although the mechanism for such IL-7 induced B
cell decline has yet not been clarified, whether it reflects
redistribution or cell death, our results indicate the possibility that
B cell apoptosis accelerated by high IL-7 levels could contribute to
the decreased number of circulating B lymphocytes.
The effects of IL-7 on B cell apoptosis may be limited under
steady-state conditions due to the low IL-7 levels. Similarly, the two
Figure 5. The effect of c-chain cytokines on IFN-c production by T cells. A. IFN-c levels were measured in supernatants of T cells cultured in
the presence of IL-2, IL-4, IL-7, IL-15 and IL-21 for five days. B. The same supernatants were tested for the ability to trigger CD95 upregulation on B
lymphocytes. Representative data out of 3 independent experiments are shown. C. Purified B cells were cultured in the presence of IL-2 or IL-15
treated T cell supernatants for 3 days and then CD95 expression was analyzed by flow cytometry. IFN-c was neutralized in the supernatants using
10 mg/ml anti-IFN-c antibodies (black lines). Histograms with grey line represent samples containing isotype control antibody, the grey filled
histograms represent samples without antibodies added and the dotted histograms represent stainings with isotype control antibody.
doi:10.1371/journal.pone.0028629.g005
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IFN-c induction with IL-7, may not act chronically and
systematically but rather at sites of ongoing massive T cell activation
or inflammation. The increasing levels of IL-7 in HIV-1 infected
individuals may, on the other hand, strongly facilitate IFN-c
production particularly in tissue niches where the cytokine is
produced and/or concentrated on the surface of stromal cells. Bone
marrow, characterized by the presence of IL-7 producing stromal
cells and memory T cells as well as secondary lymphoid tissues
where lymphocytes migrate along an IL-7 producing fibroblast
network may represent niches where IL-7 can influence B cell
homeostasis. The fibroblast reticular cell network, however, might
collapse inresponse to prolonged CD4+ T cell depletion andtheIL-
7 production in the lymphoid tissues might decline during the
courseofdisease progression [53]. Itisnoteworthythat IFN-c might
increase the production of IL-7 by epithelial or bone marrow
stromal cells [54] suggesting a positive regulatory loop when the IL-
7 induced IFN-c can further increase IL-7 production. However,
further knowledge is clearly needed on the source of high IL-7 levels
in order to better understand the localization, targets and effects of
this cytokine in HIV-1 infected individuals.
The effects of IL-7 induced IFN-c production among T cells
might be multiple. Such mechanism may contribute to a better
immunity at the price of less regulated and less localized TH1 type
responses. On the other hand, when IFN-c production is
chronically supported and localized to IL-7 producing tissues or
cells, rather than to sites of antigen-specific T cell activation, high
IFN-c levels may affect B cells independently of BCR triggering in
the GC reactions. The IFN-c induced CD95 upregulation on
resting B cells may contribute to the increased apoptosis sensitivity
of B cells observed in HIV-1 infected individuals and to the
decreased maintenance of antigen-specific memory B cells.
Taken together, we presented a novel mechanism that implicates
the T cell stimulatory environment associated with lymphopenia in
bystander B cell apoptosis triggered by Fas activation.
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